On 2014 Feb 14, David Keller commented:

Ibuprofen use is associated with lower risk of Parkinson's Disease

In the March 8, 2011 issue of Neurology (published online on March 2), a large prospective study by Gao demonstrated that users of ibuprofen had a significantly lower risk of developing Parkinson's Disease (PD) than non-users (relative risk = 0.62, p=0.02). He also demonstrated a significant dose-response relationship between the number of tablets of ibuprofen taken per week and reduction of PD risk. In addition, he found that PD risk was not significantly affected by the use of other NSAID's or aspirin. Gao also published a meta-analysis of prior studies, which revealed a highly significant relative risk of 0.73 for ibuprofen users developing PD, versus no benefit for users of other NSAID's.

I believe that the results cited above render the findings of the Driver study irrelevant with respect to ibuprofen, since Driver grouped together users of all NSAID's. By failing to separately analyze ibuprofen, its possible benefits may have been diluted out by the non- beneficial effects of other NSAID's.

It is imperative at this time that ibuprofen be studied further as a possible neuro-protective agent in PD. The null results of the Driver study should be ignored. The best available evidence clearly supports funding for a prospective, randomized, double-blind placebo-controlled interventional trial of ibuprofen as a neuro-protective agent in early Parkinson's Disease.

On 2014 Feb 14, David Keller commented:

Ibuprofen use is associated with lower risk of Parkinson's Disease

In the March 8, 2011 issue of Neurology (published online on March 2), a large prospective study by Gao demonstrated that users of ibuprofen had a significantly lower risk of developing Parkinson's Disease (PD) than non-users (relative risk = 0.62, p=0.02). He also demonstrated a significant dose-response relationship between the number of tablets of ibuprofen taken per week and reduction of PD risk. In addition, he found that PD risk was not significantly affected by the use of other NSAID's or aspirin. Gao also published a meta-analysis of prior studies, which revealed a highly significant relative risk of 0.73 for ibuprofen users developing PD, versus no benefit for users of other NSAID's.

I believe that the results cited above render the findings of the Driver study irrelevant with respect to ibuprofen, since Driver grouped together users of all NSAID's. By failing to separately analyze ibuprofen, its possible benefits may have been diluted out by the non- beneficial effects of other NSAID's.

It is imperative at this time that ibuprofen be studied further as a possible neuro-protective agent in PD. The null results of the Driver study should be ignored. The best available evidence clearly supports funding for a prospective, randomized, double-blind placebo-controlled interventional trial of ibuprofen as a neuro-protective agent in early Parkinson's Disease.